Advanced search
Publication Cover
Expert Review of Vaccines Volume 15, 2016 - Issue 2
Submit an article Journal homepage
892
Views
22
CrossRef citations to date
0
Altmetric
Reviews

Development of Group A streptococcal vaccines: an unmet global health need

Meru SheelTelethon Kids Institute, The University of Western Australia, Perth, Australia
,
Nicole J MorelandMaurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand;School of Biological Sciences, University of Auckland, Auckland, New Zealand
,
John D FraserMaurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand;School of Medical Sciences, University of Auckland, Auckland, New Zealand
&
Jonathan CarapetisTelethon Kids Institute, The University of Western Australia, Perth, Australia;Princess Margaret Hospital for Children, Perth, AustraliaCorrespondence[email protected]
Pages 227-238 | Received 06 Sep 2015, Accepted 03 Nov 2015, Published online: 03 Dec 2015

References

••Detailed review of group A streptococcus pathogensis

  • RHD Australia (ARF/RHD writing group). Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease. 2nd ed. Darwin: National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand; 2012.
  • Steer A. Status of vaccine research and development of vaccines for streptococcus pyogenes [Internet]. WHO Product Development for Vaccines Advisory Committee (PD-VAC) meeting – 2015; 2015 Sep 7–9; Salle D, WHO headquarters, Geneva [cited 2015 Sep 1]. Available from: http://who.int/immunization/research/meetings_workshops/pdvac/en/

•This report was presented to the WHO in 2014

  • Carapetis JR, Wolff DR, Currie BJ. Acute rheumatic fever and rheumatic heart disease in the top end of Australia’s Northern Territory. Med J Aust. 1996;164(3):146–149.
  • Milne RJ, Lennon D, Stewart JM, et al. Mortality and hospitalisation costs of rheumatic fever and rheumatic heart disease in New Zealand. J Paediatr Child Health. 2012;48(8):692–697.
  • Milne RJ, Lennon DR, Stewart JM, et al. Incidence of acute rheumatic fever in New Zealand children and youth. J Paediatr Child Health. 2012;48(8):685–691.
  • Moreland NJ, Waddington CS, Williamson DA, et al. Working towards a group A streptococcal vaccine: report of a collaborative Trans-Tasman workshop. Vaccine. 2014;32(30):3713–3720.
  • Carapetis JR, Steer AC, Mulholland EK, et al. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5(11):685–694.

•Report on global burden of GAS diseases. The data presented here is summary of a detailed report prepared for the WHO

  • de Dassel JL, Ralph AP, Carapetis JR. Controlling acute rheumatic fever and rheumatic heart disease in developing countries: are we getting closer? Curr Opin Pediatr. 2015;27(1):116–123.
  • Zuhlke LJ, Steer AC. Estimates of the global burden of rheumatic heart disease. Glob Heart. 2013;8(3):189–195.
  • Zuhlke L, Engel ME, Karthikeyan G, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J. 2015;36(18):1115–1122.

••A large-scale study collecting complementary data describing patient characteristics and treatment pattern of RHD patients in developing countries

  • Gewitz MH, Baltimore RS, Tani LY, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation 2015;131(20):1806–1818.

••Recently revised Jones Criteria incorporating guidelines for diagnosis of ARF in high incidence settings

  • Roberts K, Colquhoun S, Steer A, et al. Screening for rheumatic heart disease: current approaches and controversies. Nat Rev Cardiol. 2013;10(1):49–58.
  • White A, Wong W, Sureshkumur P, et al. The burden of kidney disease in indigenous children of Australia and New Zealand, epidemiology, antecedent factors and progression to chronic kidney disease. J Paediatr Child Health. 2010;46(9):504–509.
  • Hoy WE, White AV, Dowling A, et al. Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life. Kidney Int. 2012;81(10):1026–1032.
  • Marshall CS, Cheng AC, Markey PG, et al. Acute post-streptococcal glomerulonephritis in the northern territory of Australia: a review of 16 years data and comparison with the literature. Am J Trop Med Hyg. 2011;85(4):703–710.
  • Steer AC, Lamagni T, Curtis N, et al. Invasive group a streptococcal disease: epidemiology, pathogenesis and management. Drugs. 2012;72(9):1213–1227.
  • Walker MJ, Barnett TC, McArthur JD, et al. Disease manifestations and pathogenic mechanisms of group A streptococcus. Clin Microbiol Rev. 2014;27(2):264–301.
  • Davies MR, Holden MT, Coupland P, et al. Emergence of scarlet fever streptococcus pyogenes emm12 clones in Hong Kong is associated with toxin acquisition and multidrug resistance. Nat Genet. 2015;47(1):84–87.
  • Bowen AC, Mahe A, Hay RJ, et al. The global epidemiology of impetigo: a systematic review of the population prevalence of impetigo and pyoderma. Plos One. 2015;10(8):e0136789.
  • Pfoh E, Wessels MR, Goldmann D, et al. Burden and economic cost of group A streptococcal pharyngitis. Pediatrics. 2008;121(2):229–234.
  • Carapetis J, Steer A. Prevention of rheumatic fever. Pediatr Infect Dis J. 2010;29(1):91–92. Author reply 92.
  • Lennon D, Stewart J, Farrell E, et al. School-based prevention of acute rheumatic fever: a group randomized trial in New Zealand. Pediatr Infect Dis J. 2009;28(9):787–794.
  • Irlam J, Mayosi BM, Engel M, et al. Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2013;6(3):343–351.
  • Carapetis JR. The stark reality of rheumatic heart disease. Eur Heart J. 2015;36(18):1070–1073.
  • Wyber R, Taubert K, Marko S, et al. Benzathine penicillin G for the management of RHD: concerns about quality and access, and opportunities for intervention and improvement. Glob Heart. 2013;8(3):227–234.
  • Steer AC, Law I, Matatolu L, et al. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis. 2009;9(10):611–616.
  • McMillan DJ, Dreze PA, Vu T, et al. Updated model of group A streptococcus M proteins based on a comprehensive worldwide study. Clin Microbiol Infect. 2013;19(5):E222–9.
  • Baroux N, D’Ortenzio E, Amedeo N, et al. The emm-cluster typing system for Group A streptococcus identifies epidemiologic similarities across the Pacific region. Clin Infect Dis. 2014;59(7):e84–92.
  • Sanderson-Smith M, De Oliveira DM, Guglielmini J, et al. A systematic and functional classification of streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development. J Infect Dis. 2014;210(8):1325–1338.

••First study to describe emm-cluster typing for GAS

  • Shulman ST, Tanz RR, Dale JB, et al. Added value of the emm-cluster typing system to analyze group A streptococcus epidemiology in high-income settings. Clin Infect Dis. 2014;59(11):1651–1652.
  • Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis. 1992;166(2):374–382.
  • McDonald M, Currie BJ, Carapetis JR. Acute rheumatic fever: a chink in the chain that links the heart to the throat? Lancet Infect Dis. 2004;4(4):240–245.

•An original study proposing the link between GAS skin infections and rheumatic fever

  • Williamson DA, Smeesters P, Steer A, et al. M-protein analysis of streptococcus pyogenes isolates associated with acute rheumatic fever in New Zealand. J Clin Microbiol. 2015;53(11):3618–3620.
  • Freschi de Barros S, De Amicis KM, Alencar R, et al. Streptococcus pyogenes strains in Sao Paulo, Brazil: molecular characterization as a basis for StreptInCor coverage capacity analysis. BMC Infect Dis. 2015;15(1):308.
  • Smeesters PR, Campos Jr. D, Van Melderen L, et al. Pharyngitis in low-resources settings: a pragmatic clinical approach to reduce unnecessary antibiotic use. Pediatrics. 2006;118(6):e1607–11.
  • Steer AC, Batzloff MR, Mulholland K, et al. Group A streptococcal vaccines: facts versus fantasy. Curr Opin Infect Dis. 2009;22(6):544–552.
  • Horstmann RD, Sievertsen HJ, Knobloch J, et al. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci USA. 1988;85(5):1657–1661.
  • Morfeldt E, Berggard K, Persson J, et al. Isolated hypervariable regions derived from streptococcal M proteins specifically bind human C4b-binding protein: implications for antigenic variation. J Immunol. 2001;167(7):3870–3877.
  • Johnsson E, Berggard K, Kotarsky H, et al. Role of the hypervariable region in streptococcal M proteins: binding of a human complement inhibitor. J Immunol. 1998;161(9):4894–4901.
  • Fischetti VA. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev. 1989;2(3):285–314.
  • Lancefield RC. Current knowledge of type-specific M antigens of group A streptococci. J Immunol. 1962;89:307–313.
  • Hu MC, Walls MA, Stroop SD, et al. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun. 2002;70(4):2171–2177.
  • McNeil SA, Halperin SA, Langley JM, et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis. 2005;41(8):1114–1122.
  • Kotloff KL, Corretti M, Palmer K, et al. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. Jama. 2004;292(6):709–715.
  • Shulman ST, Tanz RR, Dale JB, et al. Seven-year surveillance of North American pediatric group A streptococcal pharyngitis isolates. Clin Infect Dis. 2009;49(1):78–84.
  • Dale JB, Penfound TA, Chiang EY, et al. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine. 2011;29(46):8175–8178.

•This study describes the reformation of the 30-valent vaccine

  • Engel ME, Muhamed B, Whitelaw AC, et al. Group A streptococcal emm type prevalence among symptomatic children in Cape Town and potential vaccine coverage. Pediatr Infect Dis J. 2014;33(2):208–210.
  • Dale JB, Penfound TA, Tamboura B, et al. Potential coverage of a multivalent M protein-based group A streptococcal vaccine. Vaccine. 2013;31(12):1576–1581.
  • Yim P. Streptococcus vaccine clinical trial to begin [Internet]. 2015 [cited 2015 Aug 25]. Available from: http://goo.gl/3FIkOX
  • Brandt ER, Hayman WA, Currie B, et al. Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology. 1996;89(3):331–337.
  • Batzloff MR, Hayman WA, Davies MR, et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis. 2003;187(10):1598–1608.
  • Batzloff M, Yan H, Davies M, et al. Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection. Indian J Med Res. 2004;119(Suppl):104–107.
  • Caro-Aguilar I, Ottinger E, Hepler RW, et al. Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197. Hum Vaccin Immunother. 2013;9(3):488–496.
  • Sheel M, Pandey M, Good MF, et al. Correlation between bioluminescence and bacterial burden in passively protected mice challenged with a recombinant bioluminescent M49 group A streptococcus strain. Clin Vaccine Immunol. 2010;17(1):127–133.
  • Sheel M. Immunogencity and efficacy of anti- S. pyogenes vaccine candidate [PhD thesis] [Internet]. Queensland University of Technology, QUT ePrints; 2010 [cited 2015 Aug 15]. Available from: http://eprints.qut.edu.au/35749/1/Meru_Sheel_Thesis.pdf
  • Pandey M, Wykes MN, Hartas J, et al. Long-term antibody memory induced by synthetic peptide vaccination is protective against streptococcus pyogenes infection and is independent of memory T cell help. J Immunol. 2013;190(6):2692–2701.
  • Good MF, Pandey M, Batzloff MR, et al. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci. Expert Rev Vaccines. 2015;14(11):1459–1470.
  • Pandey M, Langshaw E, Hartas J, et al. A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia. J Immunol. 2015;194(12):5915–5925.

•This study describes the use of a mouse model for pyoderma to study GAS skin infections and vaccine efficacy

  • Maamary PG, Ben Zakour NL, Cole JN, et al. Tracing the evolutionary history of the pandemic group A streptococcal M1T1 clone. Faseb J. 2012;26(11):4675–4684.
  • Maamary PG, Sanderson-Smith ML, Aziz RK, et al. Parameters governing invasive disease propensity of non-M1 serotype group A streptococci. J Innate Immun. 2010;2(6):596–606.
  • Hidalgo-Grass C, Dan-Goor M, Maly A, et al. Effect of a bacterial pheromone peptide on host chemokine degradation in group A streptococcal necrotising soft-tissue infections. Lancet. 2004;363(9410):696–703.
  • Chiappini N, Seubert A, Telford JL, et al. Streptococcus pyogenes SpyCEP influences host-pathogen interactions during infection in a murine air pouch model. Plos One. 2012;7(7):e40411.
  • Bowen AC, Tong S, Chatfield MD, et al. The microbiology of impetigo in Indigenous children: associations between streptococcus pyogenes, staphylococcus aureus, scabies, and nasal carriage. BMC Infect Dis. 2014;14(1):3854.
  • Romani L, Steer AC, Whitfeld MJ, et al. Prevalence of scabies and impetigo worldwide: a systematic review. Lancet Infect Dis. 2015;15(8):960–967.

••A comprehensive review of the global burden of impetigo and scabies

  • Guilherme L, Alba MP, Ferreira FM, et al. Anti-group A streptococcal vaccine epitope: structure, stability, and its ability to interact with HLA class II molecules. J Biol Chem. 2011;286(9):6989–6998.
  • Postol E, Alencar R, Higa FT, et al. StreptInCor: a candidate vaccine epitope against S. pyogenes infections induces protection in outbred mice. Plos One. 2013;8(4):e60969.
  • Guerino MT, Postol E, Demarchi LM, et al. HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate. Vaccine. 2011;29(46):8250–8256.
  • Guilherme L, Postol E, Ferreira FM, et al. StreptInCor: a model of anti-streptococcus pyogenes vaccine reviewed. Auto Immun Highlights. 2013;4(3):81–85.
  • De Amicis KM, Freschi de Barros S, Alencar RE, et al. Analysis of the coverage capacity of the StreptInCor candidate vaccine against streptococcus pyogenes. Vaccine. 2014;32(32):4104–4110.
  • Steer AC, Dale JB, Carapetis JR. Progress toward a global group a streptococcal vaccine. Pediatr Infect Dis J. 2013;32(2):180–182.
  • Bensi G, Mora M, Tuscano G, et al. Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case. Mol Cell Proteom MCP. 2012;11(6):M111 015693.

••Paper describes the use of reverse vaccinology to identify novel vaccine candidates

  • Massell BF, Honikman LH, Amezcua J. Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA. 1969;207(6):1115–1119.
  • Massell BF, Michael JG, Amezcua J, et al. Secondary and apparent primary antibody responses after group A streptococcal vaccination of 21 children. Appl Microbiol. 1968;16(3):509–518.
  • Bisno AL, Rubin FA, Cleary PP, et al. National Institute of A, Infectious D. Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles–report of a National Institute of Allergy and Infectious Diseases workshop. Clin Infect Dis. 2005;41:(8):1150–1156.
  • Martin WJ, Steer AC, Smeesters PR, et al. Post-infectious group A streptococcal autoimmune syndromes and the heart. Autoimmun Rev. 2015;14(8):710–725.

•Excellent review discussing immune responses to GAS associated immune sequelae

••Detailed review on correlates of protection for GAS vaccines

  • Lancefield RC. Differentiation of group A streptococci with a common R antigen into three serological types, with special reference to the bactericidal test. J Exp Med. 1957;106(4):525–544.
  • Romero-Steiner S, Frasch C, Concepcion N, et al. Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol. 2003;10(6):1019–1024.
  • Romero-Steiner S, Libutti D, Pais LB, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol. 1997;4(4):415–422.
  • Alam FM, Turner CE, Smith K, et al. Inactivation of the CovR/S virulence regulator impairs infection in an improved murine model of Streptococcus pyogenes naso-pharyngeal infection. Plos One. 2013;8(4):e61655.
  • Skinner JM, Caro-Aguilar IC, Payne AM, et al. Comparison of rhesus and cynomolgus macaques in a Streptococcus pyogenes infection model for vaccine evaluation. Microb Pathog. 2011;50(1):39–47.
  • Rivera-Hernandez T, Carnathan DG, Moyle PM, et al. The contribution of non-human primate models to the development of human vaccines. Discov Med. 2014;18(101):313–322.
  • Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol. 2011;11(1):57–64.
  • Tacket CO, Cohen MB, Wasserman SS, et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect Immun. 1999;67(12):6341–6345.
  • Polly SM, Waldman RH, High P, et al. Protective studies with a group A streptococcal M protein vaccine. II. Challange of volunteers after local immunization in the upper respiratory tract. J Infect Dis. 1975;131(3):217–224.
  • Fox EN, Waldman RH, Wittner MK, et al. Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers. J Clin Invest. 1973;52(8):1885–1892.
  • D’Alessandri R, Plotkin G, Kluge RM, et al. Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus. J Infect Dis. 1978;138(6):712–718.
  • Tapia MD, Sow SO, Tamboura B, et al. Streptococcal pharyngitis in schoolchildren in Bamako, Mali. Pediatr Infect Dis J. 2015;34(5):463–468.
  • Danchin MH, Rogers S, Kelpie L, et al. Burden of acute sore throat and group A streptococcal pharyngitis in school-aged children and their families in Australia. Pediatrics. 2007;120(5):950–957.
  • Steer AC, Jenney AW, Kado J, et al. Prospective surveillance of streptococcal sore throat in a tropical country. Pediatr Infect Dis J. 2009;28(6):477–482.
  • Dale JB, Fischetti VA, Carapetis JR, et al. Group A streptococcal vaccines: paving a path for accelerated development. Vaccine. 2013;31(Suppl 2):B216–22.
  • Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012;380(9859):2095–2128.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.